The program embodies the principles in the recently signed Homeland
Security Presidential Directive-18, which directs Federal agencies to
undertake efforts to combat biological threats for which we do not
currently have countermeasures. Funding of the program at the requested
level for FY 2008 is required to maintain execution of the FY 2006 and
FY 2007 innovations and to address capability gaps. A reduction of $100
million would continue to underfund this effort and dramatically reduce
the potential to develop and deliver products for transition to advanced
development by the end of FY 2010."
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not
purely historical, including statements regarding Peregrine
Pharmaceuticals' intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements involve risks and uncertainties
including, but not limited to, the ris
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved